课题基金 / 基金详情

Institutional Career Development Core

Institutional Career Development Core
机构职业发展核心
批准号:
9983234
负责人:
Charles C Miller
金额:
$116.64万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-24 至 2024-06-30

项目摘要

项目成果

Charles C Miller的其他基金

相似基金

相关文献

中文摘要
翻译
很少有单一的机构能够满足所有类型的临床和翻译(C&T)(T1-T2)的不同培训需求。 T4)调查员。德克萨斯大学休斯顿健康科学中心(UTHSC-H)和UT MD 安德森癌症中心(UT MDACC)拥有独特的合作伙伴关系,优势互补, 让我们能够满足这些需求。大多数T1-2培训是在UT MDACC和我们的联合 生物医学科学研究生院。T2-T4研究是基于UTHSC-H麦戈文医学院, 与我们的公共卫生,生物医学信息学,护理和牙科学院合作。我们 申请CTSA每年资助6名KL 2学者。最大限度地提高C&T的数量和成就 我们的中心培训的调查人员,我们将利用CTSA资金,每年还支持6名机构学者 并加强我们的计划,在整个庞大的德克萨斯医疗中心培养熟练的C&T调查人员 (TMC)(每年9200张床位和1000万次就诊),为极其多样化的患者群体提供服务。我们 该计划包括:1)临床和转化研究课程(510名参与者在过去5年; 11 学者所需的基本课程/研讨会); 2)MS课程和临床研究学位(65 TMC 教师和研究员在过去5年;可选的学者和量身定制的职业发展计划);和3) 我们核心的中心焦点:强化导师计划,(28 KL 2或机构学者和27其他 在过去5年中,C&T研究人员非常成功地帮助我们的学员, 机构,贝勒医学院和其他地方,以确保主要赠款,发表在高影响力的期刊 (NEJM,JAMA等),并成为机构和国家学术领导人。 特殊优势包括我们的学者的研究成功涉及多学科团队和其他CTSA 中心;改善孕妇、儿童和青少年的医疗保健的交付、安全性和有效性, 任何年龄的弱势患者;使用n-of-1试验,贝叶斯推进C&T研究方法 方法和经济分析;并显示减少卫生系统成本,以确保充分的 偿还费用,以维持和扩大经改进的护理提供办法。下一个周期的创新将 增强这些优势,加强T1研究培训,团队科学研究,以及与行业的互动, 并通过一种新的LHC咨询服务,一种持续的 社区参与计划,以及一个特殊的IRB小组,以促进和促进科学和道德, 比较有效性研究、紧急治疗试验以及实施/取消实施 research.这些和其他核心功能将促进LHC内学者的职业发展 系统,以最快地推进临床护理和不同人群的健康。通过这些创新, 我们的业绩记录、基础设施和机构支持,CTSA的资金将可以预见地产生巨大的回报 通过培养创新、协作、严谨和富有成效的C&T调查人员。
英文摘要
Few single institutions can meet the differing training needs of all types of clinical and translational (C&T) (T1- T4) investigators. The University of Texas Health Science Center at Houston (UTHSC-H) and the UT MD Anderson Cancer Center (UT MDACC) have a unique partnership with overlapping strengths and close proximity that allow us to meet these needs. Most T1-2 training is provided at UT MDACC and our joint Graduate School of Biomedical Sciences. T2-T4 research is based at UTHSC-H McGovern Medical School in collaboration with our Schools of Public Health, Biomedical informatics, Nursing, and Dentistry. We are applying for a CTSA to fund 6 KL2 Scholars per yr. To maximize the number and achievements of the C&T investigators trained by our hub, we will leverage CTSA funding to also support 6 Institutional Scholars per yr and enhance our program developing skilled C&T investigators throughout the immense Texas Medical Center (TMC) (9200 beds and 10 million encounters per yr) serving an extremely diverse patient population. Our Program includes: 1) the Clinical and Translational Research Curriculum (510 participants in past 5 yrs; 11 basic courses/workshops required for Scholars); 2) MS Courses & Degree in Clinical Research (65 TMC faculty & fellows in the past 5 yrs; optional for Scholars & tailored to an career development plan); and 3) the central focus of our Core: an Intensive Mentorship Program, (28 KL2 or Institutional Scholars & 27 other talented C&T investigators in past 5 yrs) that has been highly successful in helping mentees from our institutions, Baylor College of Medicine, and elsewhere to secure major grants, publish in high impact journals (NEJM, JAMA, and others), and become institutional and national academic leaders. Special strengths include our Scholars’ research success involving multidisciplinary teams and other CTSA centers; improving the delivery, safety, and effectiveness of healthcare for pregnant women, children, and disadvantaged patients of any age; advancing the methods of C&T research using n-of-1 trials, Bayesian methods, and economic analyses; and showing reduced health system costs to secure adequate reimbursements to sustain and expand improved approaches to care delivery. Innovations in the next cycle will augment these strengths, enhance T1 research training, team science research, and interaction with industry, and promote learning health care (LHC) research through a novel LHC consultation service, a continuous community engagement program, and a special IRB panel to facilitate and advance the science and ethics of comparative effectiveness research, trials of emergency therapies, and implementation/de-implementation research. These and other Core features will promote the career development of Scholars within a LHC system to most rapidly advance clinical care and the health of diverse populations. With these innovations and our track record, infrastructure, and institutional support, CTSA funding will predictably produce a large return by developing innovative, collaborative, rigorous, and productive C&T investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Institutional Career Development Core
Institutional Career Development Core
Institutional Career Development Core
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: